GP 681
Alternative Names: GP-681Latest Information Update: 30 Aug 2024
At a glance
- Originator Jiangxi Qingfeng Pharmaceutical
- Class Antivirals
- Mechanism of Action Endonuclease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Influenza virus infections
- Phase I Liver disorders
Most Recent Events
- 30 Aug 2024 Jiangxi Qingfeng Pharmaceutical plans a phase III trial for Influenza virus infections (In adolescents, In adults, In the elderly) (PO) in August 2024 (NCT06573008)
- 31 Oct 2023 Jiangxi Qingfeng Pharmaceutical completes a phase I trial (In volunteers) in China (PO) (NCT05789342)
- 31 Oct 2023 Jiangxi Qingfeng Pharmaceutical completes a phase III trial for Influenza virus infections (In Children, In adolescents, In adults) (PO, Tablet) (NCT05474755)